Lexaria Bioscience

Lexaria Bioscience R&D per Employee

The R&D Spending per Employee of Lexaria Bioscience (LEXX) as of Nov 19, 2026 is 1.65 M USD. In the previous year, R&D Spending per Employee was 472,113.00 USD — a change of 249.02% (higher).

R&D per Employee

1.65 MUSD

YoY

249.02%

Last updated:

R&D Spending per Employee of Lexaria Bioscience is 2025 1.65 M USD. R&D Spending per Employee of Lexaria Bioscience was 2024 472,113.00 USD. It decreases by 249.02% higher compared to the previous year.

The Lexaria Bioscience R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
98,572.80 USD
Jan 1, 2019
111,146.00 USD
Jan 1, 2020
77,414.80 USD
Jan 1, 2021
252,579.00 USD
Jan 1, 2022
368,535.00 USD
Jan 1, 2023
733,344.20 USD
Jan 1, 2024
472,113.00 USD
Jan 1, 2025
1.65 M USD
The Lexaria Bioscience R&D per Employee history
YEARR&D per EmployeeYoY
1.65 MUSD+249.02%
472,113.00USD-35.62%
733,344.20USD+98.99%
368,535.00USD+45.91%
252,579.00USD+226.27%
77,414.80USD-30.35%
111,146.00USD+12.76%
98,572.80USD+809.59%
10,837.00USD+500.45%
1,804.80USD-93.84%
29,293.20USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lexaria Bioscience Stock analysis

What does Lexaria Bioscience do? Lexaria Bioscience Corp. generates revenue through its DehydraTECH drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients. The company operates in two segments: Intellectual Property and Products, licensing its patented technology to partners in the pharmaceutical industry. DehydraTECH formulations improve oral absorption and have demonstrated enhanced delivery into brain tissue, supporting applications for intraoral and topical administration. The firm holds 35 granted patents and numerous pending patents worldwide, leveraging its intellectual property portfolio for licensing agreements. The company's primary customers are pharmaceutical firms seeking to improve drug delivery for oral, intraoral, and topical formulations. These partners utilize DehydraTECH to increase the effectiveness of active molecules, particularly for applications requiring higher bioavailability or targeted brain delivery. Lexaria's technology is positioned to support the development of new pharmaceutical products without direct manufacturing involvement. Lexaria's business model relies on licensing its patented DehydraTECH technology to pharmaceutical companies, generating income through intellectual property agreements. The company does not produce or sell finished pharmaceutical products but instead focuses on technology licensing and intellectual property management. Its subsidiary Lexa is part of the corporate structure but does not drive revenue generation. Lexaria Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lexaria Bioscience stock

R&D Spending per Employee of Lexaria Bioscience is 1.65 M USD in 2025.

R&D Spending per Employee of Lexaria Bioscience changed from 472,113.00 USD to 1.65 M USD, representing a 249.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Lexaria Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Lexaria Bioscience

All Key Metrics — Lexaria Bioscience